Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterium tuberculosis DNA topoisomerase IV is a protein complex that is notably absent from the Mycobacterium tuberculosis (Mtb) genome, making it an invalid therapeutic target (Cole et al., 1998, Nature). In most bacterial species, DNA topoisomerase IV is a type II topoisomerase composed of ParC and ParE subunits responsible for decatenating daughter chromosomes during DNA replication. However, Mtb is unique in that it lacks the parC and parE genes and instead utilizes a single type II topoisomerase, DNA gyrase, to perform both supercoiling and decatenation functions (Manjunatha et al., 2002, Nucleic Acids Research). While fluoroquinolones are often described as dual-target inhibitors of both DNA gyrase and topoisomerase IV in other bacteria, their bactericidal activity in Mtb is mediated solely through the inhibition of DNA gyrase (Aubry et al., 2006, Antimicrobial Agents and Chemotherapy). Consequently, any reference to topoisomerase IV as a target in Mtb is biologically inaccurate. This absence of a second type II topoisomerase simplifies the target landscape for Mtb but also means that resistance mutations in DNA gyrase can more readily lead to high-level fluoroquinolone resistance (Makarov et al., 2007, Journal of Biological Chemistry).
Not applicable due to the absence of the target in Mycobacterium tuberculosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis DNA topoisomerase IV (Topo IV) (Topo IV).